We always have something going on at Juno.
Want to keep up with our most recent developments?
Have a read of our latest news, new product launches and business news.
Filter News by:

Juno Pharmaceuticals Launches Schedule 3 Naloxone Hydrochloride

Juno Pharmaceuticals is excited to announce the launch of Junalox (naloxone hydrochloride) 400 mcg/1 mL solution for injection, the first product of its type registered as a Schedule 3 - Pharmacist Only Medicine. Read more

Juno Acquires Local Portfolio of Essential Injectable Medicines from AstraZeneca

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals Pty Ltd is pleased to announce the acquisition of a local portfolio of essential injectable medicines from AstraZeneca Pty Ltd.  This acquisition will see Juno’s product range grow to over 60 molecules, focussed mainly in the hospital segment. Read more

Juno Launches New Range of Polypropylene Pre-Filled Syringes

Juno is pleased to announce the launch of their new range of polypropylene pre-filled syringes, supplied by Aguettant, a leading French manufacturer of injectable medicines. Read more

Juno Pharmaceuticals $30,000 Emerging Researcher Grant

Juno’s support of the Society of Hospital Pharmacists of Australia (SHPA) has today been strengthened, with the announcement of a new $30,000 research grant. The provision of this grant will provide up and coming Australian clinical pharmacists with an unprecedented opportunity to improve patient safety in the use of high-risk medicines. Read more

Amneal Portfolio Acquisition

Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers. Read more